Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms?
Mariko Tsuda, Junichi Kiyasu · 2026
Read Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms? by Mariko Tsuda, Junichi Kiyasu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13265225.txt.
Description
Mariko Tsuda and Junichi Kiyasu discuss where a combined lymphoma regimen fits in current care, in a 2026 article. Relapsed diffuse large B-cell lymphoma is hard to treat when stem cell transplant is not an option. New immune therapies have widened choices yet complicated sequencing. Older or frail patients often cannot receive intensive cell therapy.
The article weighs epcoritamab, an off-the-shelf immune drug, alone and with two chemotherapy drugs. Earlier trial results showed durable responses in heavily pretreated patients. Open questions include who should get cell therapy first and how combinations compare. The authors call for more data to guide placement.
Catalog record
| CREATOR | Mariko Tsuda, Junichi Kiyasu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |